Yakhak Hoeji最新文献_第2页

Analysis of Socioeconomic Indirect Cost of Premature Death in Patients with HER2-positive Metastatic Breast Cancer (MBC) using Nationwide Claims Data 使用全国索赔数据分析her2阳性转移性乳腺癌(MBC)患者过早死亡的社会经济间接成本

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.189

Hwa Yeon Ko, Ahhyung Choi, Bin Hong, Ji-Hwan Bae, I. Oh, Sun-Kyeong Park, Yeon-Hee Park, Ju-Young Shin

{"title":"Analysis of Socioeconomic Indirect Cost of Premature Death in Patients with HER2-positive Metastatic Breast Cancer (MBC) using Nationwide Claims Data","authors":"Hwa Yeon Ko, Ahhyung Choi, Bin Hong, Ji-Hwan Bae, I. Oh, Sun-Kyeong Park, Yeon-Hee Park, Ju-Young Shin","doi":"10.17480/psk.2023.67.3.189","DOIUrl":"https://doi.org/10.17480/psk.2023.67.3.189","url":null,"abstract":"The premature deaths caused by human epidermal growth factor receptor-2 protein (HER2) positive metastatic breast cancer (MBC) among working age groups result in significant socioeconomic losses. This study aims to quantify the socioeconomic burden of disease in female patients and provide evidence that can inform healthcare policy decisions. We identified deaths from HER2-positive MBC over the period from 2007 to 2021, using nationwide claims data of South Korea. Then, we estimated years of potential life lost (YPLL), years of potential productivity lost (YPPLL), and cost of productivity loss (CPL) to quantify socioeconomic burden of the disease. During the period from 2011 to 2020, a total of 3,576 patients died from HER2-positive MBC. The total YPLL over the period of 10 years from 2011 to 2020 was 128,605 years, corresponding to an average of approximately 36.0 years per deceased patient. The total YPPLL during the same period was 55,608 years, corresponding to an average of approximately 15.6 years per deceased patient. Additionally, total CPL of approximately 310 million won per deceased patient was incurred. All three disease burden indicators were highest among the age group of 40 to 54 years, which are individuals in their most productive time of life.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91096780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Approval Status of COVID-19 Vaccines and Treatments in Korea, the US, and Europe 韩国、美国、欧洲新冠肺炎疫苗和治疗方法批准情况的比较

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.158

Yeon-Kyeng Lee, Eui-Kyung Lee

{"title":"Comparison of Approval Status of COVID-19 Vaccines and Treatments in Korea, the US, and Europe","authors":"Yeon-Kyeng Lee, Eui-Kyung Lee","doi":"10.17480/psk.2023.67.3.158","DOIUrl":"https://doi.org/10.17480/psk.2023.67.3.158","url":null,"abstract":"As demand for COVID-19 vaccines and treatments has soared, each country has applied appropriate approval/authorization system according to circumstances, such as emergency use authorization, conditional marketing approval, or other rapid procedures to introduce COVID-19 related items quickly. This study compared and analyzed the approval/authorization status of COVID-19 vaccines and treatments in Korea, the United States, and Europe. There were differences in the number and types of approved vaccines and treatments and also in the approval procedures used across countries. The United States adopted the emergency use authorization system, and Europe utilized the conditional marketing authorisation system, while Korea mainly applied conditional approval for vaccines and emergency use authorization for treatments. After initial approval in the US, Europe, most vaccines and treatments were introduced with delay in Korea. For instance, the average of Drug lag time for vaccines was about two months(61.5days). In the case of treatments, the difference between Drug lag time among items was relatively large. Considering that Korea's review period for drug approval is similar to that of the United States or Europe, it is necessary to proceed more quickly with approval applications and emergency authorization reviews in the event of other public health emergencies in the future.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77054223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Product Information for COVID-19 Treatments Marketing Authorized or Emergency Use Approved in Korea 韩国已批准上市或紧急使用的COVID-19治疗药物的产品信息比较

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.145

Min Joung Choi, Hyun-Ok Seo, H. Doh, Younglim Kim, Kyoung Suk Choi, Younjoo Park, Kyung Won Seo, J. Joung, Ji Yeon Kim, In Suk Park, W. Lee, S. Ki

{"title":"Comparison of Product Information for COVID-19 Treatments Marketing Authorized or Emergency Use Approved in Korea","authors":"Min Joung Choi, Hyun-Ok Seo, H. Doh, Younglim Kim, Kyoung Suk Choi, Younjoo Park, Kyung Won Seo, J. Joung, Ji Yeon Kim, In Suk Park, W. Lee, S. Ki","doi":"10.17480/psk.2023.67.3.145","DOIUrl":"https://doi.org/10.17480/psk.2023.67.3.145","url":null,"abstract":"In a situation where the development of various treatments is urgently needed to overcome the global outbreak of coronavirus disease 2019 (COVID-19) and the sequential emergence of new variant viruses, Ministry of Food and Drug Safety (MFDS) made tremendous efforts to promptly supply the safe and effective therapeutics manufactured by local and global companies through accelerated marketing authorization or emergency use approvals. To date, seven products (including overlapped) have received marketing authorization or emergency use approvals from MFDS, and their indicated patient group according to the severity, efficacy, and safety information are different by each products. Therefore, this study is to compare the product information and the major clinical outcomes obtained from clinical studies of COVID-19 treatments authorized or approved for emergency use in Korea and to introduce the MFDS’s efforts for establishment of accelerated approval system for COVID-19 treatment and development of relevant guidelines. It is hoped that this study will serve as a reference for the latecomers who is preparing the development of therapeutics for emerging infectious diseases in the future.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"90 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83896239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of Umbraulva japonica on the Stimulation of Anagen Phase 锦葵对促生长期的影响

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.182

Jung-il Kang, Youri Kim, Hae-Sic Kim, E. Yoo, Hee-kyoung Kang

引用次数: 0

A study on Establishment of Stability Test and Biopharmaceutical Analysis Support Center 稳定性试验与生物制药分析支持中心的建立研究

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.167

K. Bang

引用次数: 0

TEC Genetic Polymorphism is Associated with TNF-α Inhibitor Treatment Response in Rheumatoid Arthritis Patients 类风湿关节炎患者TEC基因多态性与TNF-α抑制剂治疗反应相关

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.176

Jun Hyeob Kim, Woojun Kim, Jin Yeon Gil, K. Min, Ji Min Han, K. Lee

引用次数: 0

Community Care and Pharmaceutical Care: Focusing on Cheonan and Jeonju 社区保健和医药保健:以天安和全州为中心

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.197

Hee-Jin Kang, S. Jang

{"title":"Community Care and Pharmaceutical Care: Focusing on Cheonan and Jeonju","authors":"Hee-Jin Kang, S. Jang","doi":"10.17480/psk.2023.67.3.197","DOIUrl":"https://doi.org/10.17480/psk.2023.67.3.197","url":null,"abstract":"As our society enters an aging society, community care is emerging to enable the elderly to spend the rest of their lives in their own neighborhoods. This is a case study of pharmacists who provided home-based pharmaceutical services as part of the leading community care programs in Jeonju and Cheonan city. By interviewing pharmacists who provided home-based pharmaceutical services, we identified the status of pharmaceutical services in community care based on their experiences. Cheonan city has provided pharmaceutical services for poly-pharmacy users, visiting them three to four times a year, and most of the initial recipients have been retained. Jeonju city has provided three types of pharmaceutical services: medication counseling, medication counseling during the transition period after discharge, and medication counseling for diabetics. Both medication counseling and the discharge transition period service were provided twice per patient. The services provided were medication reorganization and medication counseling. The pharmacist thought that they had a better understanding of the senior and could focus on patient care. They had difficulty in preparing for the service in advance due to inadequate records of medication history, and medication reconciliation, and needed various contents to increase patient interest and pharmacist expertise. In order for the visiting pharmacy program to operate more effectively in community care in the future, it is necessary to increase the effectiveness of visiting pharmacy program by establishing an information-sharing platform and developing and disseminating various visiting pharmacy program.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73449064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid-based Liquid Crystalline Phases for Biocompatible and Versatile Drug Delivery 用于生物相容性和多功能药物传递的脂基液晶相

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.137

Sung-Hyun Kim, Minyoung Seo, Hyung-sik Lim, Jin-Tae Hong

{"title":"Lipid-based Liquid Crystalline Phases for Biocompatible and Versatile Drug Delivery","authors":"Sung-Hyun Kim, Minyoung Seo, Hyung-sik Lim, Jin-Tae Hong","doi":"10.17480/psk.2023.67.3.137","DOIUrl":"https://doi.org/10.17480/psk.2023.67.3.137","url":null,"abstract":"The purpose of the paper was to overview the liquid crystalline phases that can be prepared with various lipids and to assess their characteristics as drug delivery systems for drugs to be administered to various routes. Glyceryl monooleate (GMO) was most frequently employed to deliver the drugs to topical, transdermal, oral, buccal and parenteral routes. In addition to bulk phase such as lamellar and cubic liquid crystalline phases, nano-sized cubosomes of GMO have offered a wide range of chances to administer drugs more precisely to oral and parenteral routes. In addition to GMO different types of lipids including phospholipids, triglycerides, fatty acids and cholesterol were able to form liquid crystalline phases even though most studies employing other lipids than GMO were focused on revealing their phase behaviors and physicochemical characteristics. However, it was expected that more research attempts will be made on utilizing new class of liquid crystalline phases that can be formed with various lipids. Based on the outcome published to date, more versatile drug delivery can be possible if new lipid materials can be developed and used to organize unique molecular orders suitable for a difficult-to-carry drugs.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"121 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79386551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in Pharmaceutical Market Structure and Generic Drug Utilization in the Korean National Health Security System (2007-2017) 2007-2017年韩国医疗保障体系药品市场结构及仿制药利用趋势

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.205

Suhyun Jang, S. Jang

{"title":"Trends in Pharmaceutical Market Structure and Generic Drug Utilization in the Korean National Health Security System (2007-2017)","authors":"Suhyun Jang, S. Jang","doi":"10.17480/psk.2023.67.3.205","DOIUrl":"https://doi.org/10.17480/psk.2023.67.3.205","url":null,"abstract":"We aimed to analyze the market structure and changes in the market share of new drugs, original drugs, and generic drugs in the pharmaceutical market over the past ten years. We utilized national health insurance claims data, including both national health insurance and medical aid, from 2007 to 2017 to establish pharmaceutical expenditure and usage data. The drugs are categorized into new drugs, original drugs (expired patents), and generic drugs. Furthermore, we classified the original drugs as single-source and multi-source original drugs based on whether generic drugs had entered the market. Market share is calculated based on the volume and value of drugs in each category. The results indicate that the total pharmaceutical expenditure increased by 1.75 times, from 10.4 trillion Korean won (KRW) in 2007 to 18.2 trillion KRW in 2017. The number of claimed ingredients and drug items also increased during the same period. In 2017, the market share of new drugs accounted for 10.3% of the total pharmaceutical expenditure, while original drugs and generic drugs accounted for 45.9% and 43.8%, respectively. The study reveals a slight decline in the market share of generics in the decade. Further sub-analyses based on formulation, medical center types, and the number of generic drugs provide additional insights into the market dynamics. These findings contribute to understanding the trends and implications of pharmaceutical expenditure and the role of generics in achieving sustainable development in national health insurance.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80541510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigation of International Status on Digital Health Policies in the Health Care Sector 卫生保健部门数字卫生政策国际现状调查

Yakhak Hoeji Pub Date : 2023-04-30 DOI: 10.17480/psk.2023.67.2.85

K. Cho, Kwang Joon Kim

引用次数: 0